Overview

Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical activity on refractory moderate-to-severe pruritus of a single intravenous (IV) dose of REGN846 in adult patients with moderate-to-severe atopic dermatitis (AD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Regeneron Pharmaceuticals